KRAS Inhibitor Market - Global Forecast 2026-2032

The KRAS inhibitor market is rapidly evolving as scientific innovation, personalized oncology approaches, and global healthcare trends reshape how leaders must approach decision-making. Success now requires strategic alignment across scientific, operational, and commercial priorities in a landscape characterized by emerging challenges and heightened opportunity.

Market Snapshot: KRAS Inhibitor Market Opportunity

The KRAS inhibitor market is showing strong growth momentum, with market size projected to increase from USD 923.85 million in 2025 to USD 968.58 million in 2026. A compound annual growth rate of 4.74% indicates the market is expected to reach USD 1.27 billion by 2032. This expansion is powered by advancements in biomarker-driven patient identification, diversified research pipelines featuring multiple mechanisms of action, and increasing adoption across global oncology networks. These factors collectively support wider access to targeted treatments and reshape competitive positioning for organizations operating in the sector.

Scope & Segmentation

Therapy Mechanisms: Focus includes covalent KRAS G12C inhibitors, pan-KRAS and pan-RAS agents, and additional indirect modulators such as SHP2 and SOS1 inhibitors.
Mutation Subtypes: Emphasis spans G12C, G12D, G12V, non-G12C, and newly actionable mutations, including those associated with treatment resistance.
Indications: Application areas involve non-small cell lung cancer, colorectal cancer, pancreatic cancer, and further solid tumors characterized by KRAS alterations.
Line of Therapy: Deployment across first-line and subsequent treatment settings, with growth in combination regimens involving immunotherapy and other targeted agents.
Formulations: Dominance of oral therapies to facilitate outpatient management, placing emphasis on adherence and persistent, real-world usage.
Regional Coverage: Coverage spans the Americas (including United States, Canada, and Latin America), Europe (Western, Central, and Eastern), Asia-Pacific (such as Japan, South Korea, China, India, and Southeast Asia), as well as the Middle East and Africa.
Distribution Channels: Distribution via hospital pharmacies, specialty clinics, major academic centers, and community-based oncology networks.

Key Takeaways for Senior Decision-Makers

KRAS inhibition has advanced from allele-selective therapies to platform solutions enabled by companion diagnostics, translating to improved real-world implementation in oncology settings.
Innovative trial designs—such as basket and adaptive models—accelerate clinical development timelines and highlight the need for integrated biomarker and data strategies to optimize outcomes.
Competitive advantage depends on managing resistance, expanding to new mutations and tumor types, and enhancing approaches to therapy sequencing and combination interventions.
Regional market access is shaped not only by clinical performance, but also by diagnostic infrastructure, reimbursement frameworks, and ecosystem partnerships influencing provider adoption.
Business continuity in this sector requires excellence in scientific portfolio management, effective execution of trials, and establishment of robust commercial and operational platforms as demand for precision oncology increases.
Resilience across the platform—including regulatory adaptation, supply dependency reduction, and value-based communication—directly supports sustainable long-term performance in a dynamic environment.

Tariff Impact: Navigating Supply Chain and Economic Shifts

New tariff policies in the United States are set to influence KRAS inhibitor market economics by increasing input expenses and lengthening procurement times for specialized intermediates and critical equipment. Senior stakeholders should adjust operational planning to accommodate these changes, with organizational priorities including:

Establishing dual sourcing strategies for key manufacturing processes to mitigate overseas supply risks.
Ensuring GMP-compliant vendor qualification, including transfer of analytical methods and relevant regulatory updates.
Optimizing logistics for clinical trials to manage higher costs of comparator drugs and diagnostic kits.
Investing in regional production capacity and strengthening supply chain resilience as treatment programs expand to address new oncologic indications.

Methodology & Data Sources

This report utilizes comprehensive secondary research—including scientific literature, regulatory documentation, clinical trial registries, and pipeline reviews—paired with primary expert interviews. Structured validation frameworks ensure credibility and decision-ready insight across competitive, operational, and geographic market dimensions.

Why This Report Matters

Empowers senior executives to benchmark the competitive landscape and anticipate evolving business needs in the KRAS inhibitor market by leveraging thorough, validated analysis.
Assists investment decisions, portfolio development, and market entry strategies with insights into resistance management, diagnostic frameworks, and evolving supply chain dynamics.
Delivers a cohesive overview of regulatory trends, evolving market expectations, and the necessary requirements for resilient, value-driven positioning in precision oncology.

Conclusion

The KRAS inhibitor market is entering a pivotal stage that demands integrated, science-based and operationally resilient strategies. Leaders who prioritize alignment across technology, diagnostics, and market access will deliver sustained patient benefit and competitive business outcomes.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. KRAS Inhibitor Market, by Indication

8.1. Colorectal Cancer
8.2. Non-Small Cell Lung Cancer
8.3. Pancreatic Cancer

9. KRAS Inhibitor Market, by Mechanism Of Action

9.1. Allosteric Inhibitors
9.2. Covalent Inhibitors
9.3. Non-Covalent Inhibitors

10. KRAS Inhibitor Market, by Mutation Type

10.1. G12C
10.2. G12D
10.3. G12V

11. KRAS Inhibitor Market, by Dosage Form

11.1. Injectable Solutions
11.2. Oral Tablets

12. KRAS Inhibitor Market, by End User

12.1. Cancer Care Centers
12.2. Hospitals
12.3. Retail Pharmacies
12.4. Specialty Clinics

13. KRAS Inhibitor Market, by Distribution Channel

13.1. Offline
13.2. Online

14. KRAS Inhibitor Market, by Region

14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific

15. KRAS Inhibitor Market, by Group

15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO

16. KRAS Inhibitor Market, by Country

16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea

17. United States KRAS Inhibitor Market
18. China KRAS Inhibitor Market

19. Competitive Landscape

19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Amgen
19.6. AnBogen Therapeutics
19.7. Applied Pharmaceutical Science
19.8. AstraZeneca
19.9. Biond Biologics
19.10. Boehringer Ingelheim
19.11. BridgeBio Oncology Therapeutics
19.12. Bristol Myers Squibb
19.13. Cardiff Oncology, Inc.
19.14. Deciphera Pharmaceuticals
19.15. Eli Lilly
19.16. Elicio Therapeutics
19.17. Erasca
19.18. Frontier Medicines
19.19. GenFleet Therapeutics
19.20. Gritstone Bio
19.21. Immuneering Corporation
19.22. Innovent Bio
19.23. InventisBio
19.24. Jacobio Pharmaceuticals
19.25. Jiangsu Hansoh Pharmaceutical
19.26. Jiangsu Hengrui Medicine Co.
19.27. Merck
19.28. Mirati Therapeutics
19.29. Novartis
19.30. Quanta Therapeutics
19.31. Revolution Medicines
19.32. Roche
19.33. Suzhou Zelgen Biopharmaceuticals
19.34. Verastem Oncology

List of Figures

FIGURE 1. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL KRAS INHIBITOR MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL KRAS INHIBITOR MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL KRAS INHIBITOR MARKET SIZE, BY PANCREATIC CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ALLOSTERIC INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COVALENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL KRAS INHIBITOR MARKET SIZE, BY NON-COVALENT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12C, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12D, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL KRAS INHIBITOR MARKET SIZE, BY G12V, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL KRAS INHIBITOR MARKET SIZE, BY INJECTABLE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL KRAS INHIBITOR MARKET SIZE, BY CANCER CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL KRAS INHIBITOR MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL KRAS INHIBITOR MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL KRAS INHIBITOR MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL KRAS INHIBITOR MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL KRAS INHIBITOR MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL KRAS INHIBITOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. AMERICAS KRAS INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 61. AMERICAS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 62. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 63. AMERICAS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 64. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 65. AMERICAS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 66. AMERICAS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 67. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 69. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 70. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 71. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 72. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 73. NORTH AMERICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 74. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 76. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 77. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 78. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 79. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 80. LATIN AMERICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 88. EUROPE KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. EUROPE KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 90. EUROPE KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 91. EUROPE KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 92. EUROPE KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 93. EUROPE KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 94. EUROPE KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 97. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 98. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 99. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 100. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 101. MIDDLE EAST KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 102. AFRICA KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. AFRICA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 104. AFRICA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 105. AFRICA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 106. AFRICA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 107. AFRICA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 108. AFRICA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 109. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 111. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 112. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 113. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 114. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL KRAS INHIBITOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 117. ASEAN KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 118. ASEAN KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 119. ASEAN KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 120. ASEAN KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 121. ASEAN KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 122. ASEAN KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. ASEAN KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 124. GCC KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GCC KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 126. GCC KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 127. GCC KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 128. GCC KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 129. GCC KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. GCC KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 133. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 134. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 136. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. EUROPEAN UNION KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 138. BRICS KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. BRICS KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 140. BRICS KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 141. BRICS KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 142. BRICS KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 143. BRICS KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 144. BRICS KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. G7 KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 146. G7 KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 147. G7 KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 148. G7 KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 149. G7 KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 150. G7 KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 151. G7 KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 152. NATO KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. NATO KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. NATO KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 155. NATO KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 156. NATO KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 157. NATO KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 158. NATO KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 159. GLOBAL KRAS INHIBITOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. UNITED STATES KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 161. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 162. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 163. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 164. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 165. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 166. UNITED STATES KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 167. CHINA KRAS INHIBITOR MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 168. CHINA KRAS INHIBITOR MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 169. CHINA KRAS INHIBITOR MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 170. CHINA KRAS INHIBITOR MARKET SIZE, BY MUTATION TYPE, 2018-2032 (USD MILLION)
TABLE 171. CHINA KRAS INHIBITOR MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 172. CHINA KRAS INHIBITOR MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 173. CHINA KRAS INHIBITOR MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this KRAS Inhibitor market report include:

Amgen
AnBogen Therapeutics
Applied Pharmaceutical Science
AstraZeneca
Biond Biologics
Boehringer Ingelheim
BridgeBio Oncology Therapeutics
Bristol Myers Squibb
Cardiff Oncology, Inc.
Deciphera Pharmaceuticals
Eli Lilly
Elicio Therapeutics
Erasca
Frontier Medicines
GenFleet Therapeutics
Gritstone Bio
Immuneering Corporation
Innovent Bio
InventisBio
Jacobio Pharmaceuticals
Jiangsu Hansoh Pharmaceutical
Jiangsu Hengrui Medicine Co.
Merck
Mirati Therapeutics
Novartis
Quanta Therapeutics
Revolution Medicines
Roche
Suzhou Zelgen Biopharmaceuticals
Verastem Oncology

Table Information

Report Attribute	Details
No. of Pages	182
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 968.58 Million
Forecasted Market Value ( USD ) by 2032	$ 1270 Million
Compound Annual Growth Rate	4.7%
Regions Covered	Global
No. of Companies Mentioned	31

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3437EUR$3,939USD£2,985GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3707EUR$4,249USD£3,220GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5025EUR$5,759USD£4,364GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6081EUR$6,969USD£5,281GBP

Market Snapshot: KRAS Inhibitor Market Opportunity

Scope & Segmentation

Key Takeaways for Senior Decision-Makers

Tariff Impact: Navigating Supply Chain and Economic Shifts

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034

KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030

KRAS Mutant Cancer - Pipeline Insight, 2025

Therapeutic Applications of Nitric Oxide in Cancer and Inflammatory Disorders. Third International Conference on Therapeutic Application of Nitric Oxide in Cancer and Inflammatory Disorders

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies. Breaking Tolerance to Antibody-Mediated Immunotherapy Volume 1